

### Tozinameran

S

#### Cutaneous sarcoid-like granulomatous reaction: case report

A 73-year-old woman developed cutaneous sarcoid-like granulomatous reaction following vaccination with tozinameran for COVID-19 [*dosage and route not stated*].

The woman presented with painful skin lesions on her arms and legs. Physical examination revealed painful erythematous violaceous nodules on her arms and legs, suggestive of erythema nodosum-like lesions. The nodules were warm, mobile and tender on palpation. She had a medical history of mild SARS-CoV-2 infection in January 2021, which was treated with acetaminophen. In March 2021, erythema nodosum-like lesions were first reported that regressed in the following weeks. However, the lesions recurred after administration of the first dose of tozinameran [BNT162b2 vaccine; Comirnaty, Pfizer/BioNTech] vaccine. During ultrasound examination in July 2021, skin lesions were observed as multiple dermo-hypodermal inflammatory lesions with a nonhomogeneous hypochoic pattern. Skin biopsy confirmed noncaseating giant-cell sarcoid granulomas. Immunohistochemistry revealed CD4<sup>+</sup> T-lymphocyte infiltrate and high CD4/CD8 ratio. She was diagnosed with SARS-CoV-2 induced sarcoid-like granulomatous reaction.

The woman was treated with methylprednisolone. Furthermore, she received ciclosporin. Her condition improved after four weeks of treatment.

Grieco T, et al. COVID-19 infection and BNT162b2 vaccine triggering sarcoid-like lesions in the same patient. Response to: Sarcoid-like reaction in a patient recovering from COVID-19 pneumonia. JAAD Case Reports 23: 162-163, May 2022. Available from: URL: <http://doi.org/10.1016/j.jdc.2021.12.042>

803667704